Alex Bastian | Vice President, Commercial Strategy
Memo Therapeutics

Alex is Vice President of Commercial & Market Access at Memo Therapeutics, a private Swiss biotech company that focused on rare virological and oncological diseases.

Prior, Alex was Vice President at AM-Pharma, a private dutch biotech company that focused on rare, kidney and critical care diseases. He was also Vice President of Value & Market Access at Galapagos NV, a Belgo-Dutch company and Incyte Corporation, an innovative biotechnology company focusing on oncology drug development.  Alex previously also led a biotech strategy market access Consulting practice in San Francisco with Bridgehead International after having started his career with industry heavyweights Pfizer (NYC) and Amgen (Switzerland).

Alex regularly speaks at conferences and has published papers, posters and abstracts on various pricing, access, and health economic themes, including: The Institute of Medicine National Cancer Policy Forum, The Institute of Medicine’s Health Care Services board, Regional Medicare Caucuses, US State Medical Society Meetings, The American Society of Hematology, ISPOR, the National Venture Capital Association, and The Association of Community Cancer Centers.

He current sits on the editorial advisory board for the Journal of Comparative Effectiveness Research. Alex is also currently completing his doctorate in public health at Johns Hopkins University.